INSIGHTS ON DRUG DISCOVERY
-
![GettyImages-2151620900 antibody, IgG]( "Discovery, Characterization Of Epitope-Diverse MMR Protein Antibodies")
Discovery, Characterization Of Epitope-Diverse MMR Protein AntibodiesLearn how these high-affinity, epitope-diverse mAbs provide a powerful toolkit to dissect the role of DNA mismatch repair (MMR) proteins in HD.
-
![GettyImages-2153976466-protein-3d-model-render]( "Mammalian Expression")
Mammalian ExpressionSee how a biotechnology company advanced an engineered protein therapeutic while navigating development, regulatory, and scalability challenges.
-
![GettyImages-1002000796-lab-research-scientist-development]( "Balancing Timelines In Outsourced R&D With GXP Compliance")
Balancing Timelines In Outsourced R&D With GXP ComplianceOutsourced R&D balances speed and quality by integrating strong governance, clear planning, and GXP compliance, enabling efficient execution while reducing risk, rework, and development delays.
-
![GettyImages-2182052428-scientist-research-mack-labs]( "Integrated Drug Discovery: Hit To PCC In 16 Months")
Integrated Drug Discovery: Hit To PCC In 16 MonthsAccelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity4/14/2026
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Mammalian Cell Line Development3/26/2026
Explores how modern cell line engineering boosts speed, stability, and scalability across biologics, with practical insights to cut risk and improve readiness for downstream development.
-
WuXia293Stable: Express What CHO Can't3/26/2026
Discover a modern 293‑based expression system built for higher purity, controlled glycosylation, and improved activity, offering a new option for teams developing complex or next‑generation biologics.
-
What Matters More In DNA-Encoded Libraries?3/16/2026
DELs can screen billions of compounds, but library quality determines meaningful results. See how thoughtful design shapes early decisions that influence which drug candidates move forward.
-
Translating Massive Data Into Therapeutic Momentum3/13/2026
New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.
DRUG DISCOVERY SOLUTIONS
-
![GettyImages-1294339670-lab-cleanroom-PPE-computer-team]( "Leveraging Proprietary CDO Platforms")
Explore how a suite of proprietary CDO platforms for BsAbs, transient expression, developability assessment, and more can help optimize every stage of development and accelerate your project timeline.
-
![GettyImages-959053706-vial-CRISPR-gene-editing-Cas9]( "CRISPR/Cas9 And Cas9 Variants")
A quick overview of this industry-changing technology as well as the newer Cas9 variants that expand its use.
-
![GettyImages-2192786673 antibodies]( "Antibody Discovery And Engineering")
The Antibody Center at Curia provides end-to-end services in antibody discovery, engineering, and development.
-
![GettyImages-2189362114-recombinant-protein-structure]( "Protein Expression And Analysis")
Curia’s expert scientists use advanced technology to produce and analyze high-quality recombinant proteins.
-
![GettyImages-155374807-molecule-molecular]( "Small Molecules Discovery")
Whether you require a particular expertise or a complete, experienced integrated small molecule discovery team, Curia can provide a high-performance solution to help turn your vision into reality.
